Showing results (51-60 of 73) with videos related to
Sort By:
Pageof 8
Nuclear Medicine and Biology|January 1, 1996
Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: dosimetry calculations incorporating cross-organ beta dosesO Ugur, L Kostakoglu, E T Hui, et al.Cancer Research|March 1, 1992
Selective radiation of hematolymphoid tissue delivered by anti-CD45 antibodyD C Matthews, C C Badger, D R Fisher, et al.AJR. American Journal of Roentgenology|March 1, 1982
Computed tomographic mammography using a conventional body scannerC H Chang, D E Nesbit, D R Fisher, et al.Cancer|February 1, 1994
A mouse model for calculating cross-organ beta doses from yttrium-90-labeled immunoconjugatesT E Hui, D R Fisher, J A Kuhn, et al.Health Physics|February 20, 1999
Experiences with high dose radiopeptide therapy: the health physics perspectiveG D Espenan, J A Nelson, D R Fisher, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 1, 1993
Dosimetry of rhenium-186-labeled monoclonal antibodies: methods, prediction from technetium-99m-labeled antibodies and results of phase I trialsH B Breitz, D R Fisher, P L Weiden, et al.Nuclear Medicine and Biology|January 1, 1995
Calculated and TLD-based absorbed dose estimates for I-131-labeled 3F8 monoclonal antibody in a human neuroblastoma xenograft nude mouse modelO Ugur, A M Scott, L Kostakoglu, et al.Cancer Research|November 1, 1991
Biodistribution and dosimetry following infusion of antibodies labeled with large amounts of 131IC C Badger, J Davis, C Nourigat, et al.Annals of the ICRP|October 1, 2019
ICRP Publication 140: Radiological Protection in Therapy with RadiopharmaceuticalsY Yonekura, S Mattsson, G Flux, et al.Lancet (London, England)|August 5, 1995
Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomasO W Press, J F Eary, F R Appelbaum, et al.Pageof 8